Tumor Necrosis Factor News and Research

RSS

Rituxan in combination with chemo improves survival in chronic lymphocytic leukemia

Genentech, Inc. and Biogen Idec have announced that two global Phase III studies in chronic lymphocytic leukemia (CLL), CLL8 and REACH, showed Rituxan (rituximab) plus chemotherapy significantly increased the time patients lived without their disease advancing, as defined by the primary endpoint of progression-free survival (PFS), when compared to chemotherapy alone.

8 Dec 2008

Vitamin E supplementation may reduce inflammation in the brain

With up to half of a person's body mass consisting of skeletal muscle, chronic inflammation of those muscles - which include those found in the limbs - can result in significant physical impairment.

5 Dec 2008

Soviet-developed immune formula boosts immune activity

A recent study on an American-made, Soviet-developed immune formula shows the product has a significant effect on immune function.

19 Nov 2008

Musculoskeletal Center wins $2.2 million to study biologics safety

The UAB Center for Education and Research on Therapeutics has won a $2.2 million federal grant to study the risks and benefits of a class of drugs called ‘biologics' -- genetically engineered agents targeting the immune system of patients with rheumatoid arthritis, Crohn's disease, psoriasis and other autoimmune disorders.

18 Nov 2008

Adalimumab therapy may reduce health-care costs for Crohn's disease patients

Inflammatory bowel disease (IBD) is a term that refers to both ulcerative colitis (UC) and Crohn's disease (CD).

12 Nov 2008

First-ever international guidelines for the treatment of psoriatic arthritis

Rheumatologists, dermatologists, and patient advocates have come together to publish the first-ever international guidelines for the treatment of psoriatic arthritis, a disease that mainly affects people who have psoriasis but also some people without it.

26 Oct 2008

Outlook for Crohn's disease improves due to new therapies

A study led by Mayo Clinic has found that infliximab (Remicade) administered alone (monotherapy) or in combination with azathioprine is a more effective treatment for patients with moderate to severe Crohn's disease than azathioprine alone.

6 Oct 2008

FDA forces manufacturers of TNF-blockers to highlight risk of fungal infections

The U.S. Food and Drug Administration today announced that the manufacturers of Humira, Cimzia, Enbrel, and Remicade must strengthen the existing warnings, in the Warnings and Precaution sections of the drugs' prescribing information and Medication Guides, on the risk of developing opportunistic fungal infections. Some patients with invasive fungal infections have died.

5 Sep 2008

Discovery of novel candidate gene for inflammatory bowel diseases

A study of Crohn's disease and ulcerative colitis in children has identified a gene that influences whether children get these diseases early in life, and points to a potential new target for treatment.

2 Sep 2008

Discovery of new genes for inflammatory bowel disease in children

Researchers have discovered two new genes that increase the risk of developing inflammatory bowel disease (IBD) in childhood.

31 Aug 2008

Researchers discover key details of how rheumatoid arthritis destroys bone

Researchers have discovered key details of how rheumatoid arthritis (RA) destroys bone, according to a study published in the Aug. 22 edition of the Journal of Biological Chemistry. The findings are already guiding attempts to design new drugs to reverse RA-related bone loss and may also address more common forms of osteoporosis with a few adjustments.

24 Aug 2008

New discovery on how rheumatoid arthritis destroys bone

20 Aug 2008

Fish oil supplements could slow wound healing

A recent study shows that popular fish oil supplements have an effect on the healing process of small, acute wounds in human skin. But whether that effect is detrimental, as researchers initially suspected, remains a mystery.

23 Jul 2008

Use of rheumatoid arthritis drug to treat Alzheimer's causes concern

New research into the treatment of Alzheimer's disease using a popular rheumatoid arthritis drug has caused some concern.

22 Jul 2008

Discovery of new anatomical path through which the brain and spleen communicate

In a major step in understanding how the nervous system and the immune system interact, scientists at The Feinstein Institute for Medical Research have identified a new anatomical path through which the brain and the spleen communicate.

21 Jul 2008

HIV-I damages the immune system early than originally thought

New research into the earliest events occurring immediately upon infection with HIV-I shows that the virus deals a stunning blow to the immune system earlier than was previously understood. According to scientists at Duke University Medical Center, this suggests the window of opportunity for successful intervention may be only a matter of days - not weeks - after transmission, as researchers had previously believed.

19 Jul 2008

Could arthritis wonder drugs provide clues for all disease?

Drugs that have helped treat millions of rheumatoid arthritis sufferers may hold the key to many more medical conditions, including atherosclerosis - a leading cause of heart disease - says the researcher who jointly invented and developed them.

From The University of Manchester 17 Jul 2008

Discovery of possible new way to block inflammation in autoimmune disease

Researchers from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the National Institutes of Health (NIH), have identified a promising new target for autoimmune disease treatment - a cell-surface receptor called DR3.

23 Jun 2008

Breakthrough in understanding tumor immune therapy

Researchers from the Tubingen University, Department of Dermatology, uncovered an entirely new understanding on how the immune system may control tumor development.

11 Jun 2008